Research programme: AAV-based gene therapeutics - Tamid Bio

Drug Profile

Research programme: AAV-based gene therapeutics - Tamid Bio

Alternative Names: AAV gene therapy - Tamid Bio; Adenoviral-associated vector-mediated gene therapy - Tamid Bio; Tamid-001

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Tamid Bio; University of North Carolina at Chapel Hill
  • Class Gene therapies
  • Mechanism of Action Gene transference; Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Keratoplasty rejection; Mucopolysaccharidosis I; Muscular dystrophies

Most Recent Events

  • 05 Dec 2017 AAV-based gene therapeutics licensed to Tamid-Bio
  • 05 Dec 2017 Preclinical trials in Keratoplasty rejection in USA (unspecified route)
  • 05 Dec 2017 Preclinical trials in Mucopolysaccharidosis I in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top